Trial Profile
Phase II Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Liposarcoma; Malignant fibrous histiocytoma; Sarcoma
- Focus Therapeutic Use
- 11 Sep 2023 Planned End Date changed from 31 Oct 2023 to 31 Oct 2025.
- 11 Sep 2023 Planned primary completion date changed from 31 Oct 2023 to 31 Oct 2025.
- 06 Feb 2023 Planned End Date changed from 31 Oct 2022 to 31 Oct 2023.